Novartis AG (NYSE: NVS), a Swiss pharmaceutical company, last week presented interim results for the primary endpoint of a Phase III trial for atrasentan in patients with IgA nephropathy (IgAN). The trial indicated that the endothelin A (ETA) receptor antagonist demonstrated a 36.1% reduction in proteinuria at 36 weeks compared to placebo. Additionally, the candidate exhibited a favorable safety profile with no new safety signals detected.
Novartis is now preparing to submit the data for regulatory review in the following month, while it progresses the development of the investigational drug for other rare kidney diseases.- Flcube.com
